RxDoctor Payments Data

Carolina Perry, MD

Family Medicine · Indianapolis, INNPI 1326451824

Payments from drug & device makers

$634in general payments, 2019–2025

Across 22 payments — averaging $28.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$140
  • GSK$125
  • Neurocrine Biosciences, Inc.$74
  • Exact Sciences$70
  • Lundbeck LLC$37
  • Biohaven Pharmaceuticals, Inc.$28
  • plus $160 from 9 others

What the payments were for

  • Food & beverage$634100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$634 in reported general payments places this provider in the 50th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$259
Medicare patients
13
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$68,056
TrulicityDulaglutide44$50,997
FarxigaDapagliflozin Propanediol18$30,109
JardianceEmpagliflozin13$18,602
Spiriva RespimatTiotropium Bromide24$18,491
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,403
Spiriva HandihalerTiotropium Bromide11$8,644
Varenicline Tartrate22$6,534
Albuterol Sulfate HfaAlbuterol Sulfate171$3,909
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,831
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,267
Atorvastatin Calcium349$2,353
Ventolin HfaAlbuterol Sulfate29$1,621
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$1,571
Nano 2nd Gen Pen NeedlePen Needle, Diabetic25$1,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$14$50,99744 claims
GSKTrelegy Ellipta$125$11,40317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →